Dehning Julia, Grunze Heinz, Hausmann Armand
Department of Medicine, Paracelsus Medical University, Salzburg, Austria.
Department of Medicine, Medical University - Psychiatry, Innsbruck, Austria.
Clin Pract Epidemiol Ment Health. 2017 May 31;13:43-48. doi: 10.2174/1745017901713010043. eCollection 2017.
The optimal duration of antidepressant treatment in bipolar depression appears to be controversial due to a lack of quality evidence, and guideline recommendations are either vague or contradictive. This is especially true for second line treatments such as bupropion that had not been subject to rigourous long term studies in Bipolar Disorder.
We report the case of a 75 year old woman who presented with treatment refractory bipolar depression. Because of insufficient response to previous mood stabilizer treatment and refractory depressive symptoms, bupropion was added to venlafaxine and lamotrigine. From there onwards, the patient improved continuously without experiencing deterioration of depression or a switch into hypomania. Our patient being on antidepressants for allmost four years experienced an obvious benefit from longterm antidepressant administration.
Noradrenergic/dopaminergic mechanisms of action may play a more prominent role in bipolar depression, and may still be underused as a therapeutic strategy in the acute phase as well as in long-term maintenance in at least a subgroup of bipolar patients. There is still a lack of evidence from RCTs, but this case report further supports antidepressant long-term continuation and the usefulness of a noradrenergic/dopaminergic antidepressant in the acute and maintenance treatment of bipolar disorder.
由于缺乏高质量证据,双相抑郁中抗抑郁药治疗的最佳时长似乎存在争议,指南建议要么含糊不清,要么相互矛盾。对于安非他酮等二线治疗药物而言尤其如此,这类药物在双相情感障碍中尚未经过严格的长期研究。
我们报告了一名75岁女性的病例,该患者患有难治性双相抑郁。由于对先前的心境稳定剂治疗反应不足且存在难治性抑郁症状,在文拉法辛和拉莫三嗪的基础上加用了安非他酮。从那时起,患者持续改善,未出现抑郁恶化或转为轻躁狂。我们的患者服用抗抑郁药近四年,长期服用抗抑郁药获得了明显益处。
去甲肾上腺素能/多巴胺能作用机制在双相抑郁中可能发挥更突出的作用,至少在一部分双相情感障碍患者的急性期和长期维持治疗中,作为一种治疗策略可能仍未得到充分利用。随机对照试验仍缺乏证据,但该病例报告进一步支持了抗抑郁药的长期持续使用以及去甲肾上腺素能/多巴胺能抗抑郁药在双相情感障碍急性期和维持期治疗中的有效性。